{"protocolSection":{"identificationModule":{"nctId":"NCT04940130","orgStudyIdInfo":{"id":"MLSPZV5"},"organization":{"fullName":"Sanaria Inc.","class":"INDUSTRY"},"briefTitle":"PfSPZ Vaccine Trial in Malian Children","officialTitle":"Phase 2 Trial of Safety, Immunogenicity, and Efficacy Against Plasmodium Falciparum Malaria of PfSPZ Vaccine in Children in Mali"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-04-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-10","type":"ACTUAL"},"completionDateStruct":{"date":"2022-12-10","type":"ACTUAL"},"studyFirstSubmitDate":"2021-06-03","studyFirstSubmitQcDate":"2021-06-17","studyFirstPostDateStruct":{"date":"2021-06-25","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-12-06","resultsFirstSubmitQcDate":"2024-01-16","resultsFirstPostDateStruct":{"date":"2024-02-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-16","lastUpdatePostDateStruct":{"date":"2024-02-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanaria Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Malaria Research and Training Center, Bamako, Mali","class":"OTHER"},{"name":"University of the Sciences, Techniques and Technologies of Bamako","class":"OTHER"},{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"In this randomized, double-blind, placebo-controlled trial, 268 healthy Malian children aged 6-10 years, residing in Bancoumana and surrounding villages, will be administered three doses of 9.0x10\\^5 Pf sporozoites (PfSPZ) of PfSPZ Vaccine (or placebo) at 1, 8, and 29-days using direct venous inoculation (DVI).\n\nThe study is composed of a single cohort with two arms (categorized by placebo control/experimental groups) designed to assess the safety, immunogenicity and protective efficacy of PfSPZ Vaccine.\n\nAll subjects will receive artemether-lumefantrine (AL) approximately 1- 2 weeks before the first dose of PfSPZ Vaccine or normal saline for clearance of Pf parasitemia. Vaccinated participants and non-immunized controls will be followed for safety and monitored for development of parasitemia through the natural malaria transmission season to estimate vaccine efficacy (VE).","detailedDescription":"This phase 2 study will enroll healthy Malian children between 6 and 10 years of age residing in Bancoumana and surrounding villages to participate in a randomized, double blind, placebo- controlled study to assess the safety, immunogenicity and protective efficacy of PfSPZ Vaccine.\n\nParticipants will be immunized with a 3-dose series of 9.0 x10\\^5 PfSPZ of PfSPZ Vaccine or normal saline (placebo) at 1, 8, and 29 days. Subjects will be screened for eligibility for enrollment. Enrollment will begin with AL dosing approximately 1-2 weeks prior to their first dose of vaccine. Volunteers will be randomized into two arms (1 vaccine arm, 1 control arm) in a 1:1 ratio.\n\nVaccinated subjects and controls will then be followed for safety and assessment for malaria infection during the subsequent malaria transmission season.\n\n268 children between the ages of 6 and 10 years old inclusive will be enrolled as follows:\n\nArm 1(PfSPZ Vaccine): (n = 134) children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, and 29 days\n\nArm 2 (normal saline): (n = 134) children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days All subjects will receive artemether-lumefantrine (AL) approximately 1- 2 weeks before the first dose of PfSPZ Vaccine or normal saline for clearance of Pf parasitemia.\n\nVaccinated participants and non-vaccinated controls will be monitored for development of Pf malaria with symptoms and Pf malaria (parasitemia) through the natural malaria transmission season to estimate vaccine efficacy (VE). During the surveillance period, both active and passive surveillance will be used to identify Pf malaria with symptoms. Blood smears will be made at any time a participant presents with a clinical syndrome consistent with malaria and read in real time, with all infections treated.\n\nIn addition, blood smears will be made every four weeks in all participants as active surveillance for Pf malaria (parasitemia). However, to avoid confounding the primary clinical endpoint, these blood smears will be read retrospectively at the end of the primary surveillance period.\n\nPrimary Case Definition:\n\nPf malaria with symptoms is defined as a positive thick blood smear at a density of \\>1000 parasites/uL (P/uL) plus:\n\n* Measured auxiliary temperature ≥ 37.5 degrees Celsius or history of fever (subjective or objective) in the last 24 hours, or,\n* Symptoms of malaria -\n\n  * Verbal individual (individual able and willing to answer questions): A verbal individual is considered symptomatic if reporting at the time of evaluation at least two of the following symptoms/symptom groups: headache, chills and/or rigors, malaise and/or fatigue, dizziness and/or light-headedness, myalgias and/or arthralgias; or\n  * Non-verbal individual (small child or any individual unable or unwilling to answer questions): A non-verbal individual is considered symptomatic if manifesting at the time of evaluation at least two of the following signs/sign groups: drowsiness, irritability and/or fussiness, inability and/or refusal to eat or drink, prostration; or\n  * Any individual: Signs of severe malaria (e.g. impairment of consciousness, severe anemia, hemoglobinuria, acute kidney injury, etc.)\n\nSecondary Case Definition:\n\nPf malaria with symptoms is defined as a positive thick blood smear at a density of \\> 0 P/uL plus:\n\n* Measured axillary temperature ≥ 37.5 degrees Celsius or history of fever (subjective or objective) in the last 24 hours, or,\n* Symptoms of malaria as defined in the primary case definition; or\n* Meeting criteria for severe malaria\n\nPf malaria is defined as:\n\n\\- At least one unambiguous asexual parasite on thick blood smear identified by two independent microscopists after each examining 0.50 μL of blood in a study participant"},"conditionsModule":{"conditions":["Malaria","Malaria,Falciparum"],"keywords":["PfSPZ Vaccine","Malaria","Plasmodium falciparum"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"randomized, placebo controlled, with concurrent arms","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"double-blinded","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":290,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1 (PfSPZ Vaccine)","type":"EXPERIMENTAL","description":"134 children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via DVI at 1, 8, and 29 days","interventionNames":["Biological: Sanaria® PfSPZ Vaccine"]},{"label":"Arm 2 (normal saline)","type":"PLACEBO_COMPARATOR","description":"134 children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days","interventionNames":["Other: Normal Saline"]}],"interventions":[{"type":"BIOLOGICAL","name":"Sanaria® PfSPZ Vaccine","description":"non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).","armGroupLabels":["Arm 1 (PfSPZ Vaccine)"]},{"type":"OTHER","name":"Normal Saline","description":"placebo control- saline","armGroupLabels":["Arm 2 (normal saline)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Possibly, Probably, or Definitely Related Serious Adverse Events (SAEs)","description":"Proportion of vaccinees compared to controls experiencing related SAEs from V1 to 26 weeks after V3","timeFrame":"From day of first vaccination until 26 weeks after 3rd vaccination (study day 1 to day 211)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Parent(s) or guardian(s) willing and able to provide consent prior to initiation of any study procedures\n2. Stated willingness of parent(s) or guardian(s) to comply with all study procedures and availability for the duration of the study\n3. Malaria comprehension exam completed by parent(s) or guardian(s) and passed with a score of ≥80% or per investigator's discretion\n4. Healthy children 6-10 years of age at enrollment (inclusive)\n5. Parent(s) or guardian(s) are able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n6. Willing to have blood samples stored for future research\n\nExclusion Criteria:\n\n1. Medical, behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant's parent and/or legal guardian to understand and comply with the study protocol\n2. Menstruating females (in order to avoid cultural implications of further assessing pregnancy potential i.e. sexual activity in this age group)\n3. Hemoglobin (Hgb), WBC, absolute neutrophils, and platelets outside the local laboratory-defined limits of normal and ≥ Grade 2 (subjects may be included at the investigator's discretion for 'not clinically significant' abnormal values)\n4. Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal and ≥ Grade 2 (subjects may be included at the investigator's discretion for 'not clinically significant' abnormal values)\n5. Infected with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C\n6. Sickle cell disease by history\n7. Taking or planning to take seasonal malaria chemoprophylaxis\n8. Clinically significant abnormal electrocardiogram (ECG) such as abnormal QTc\n9. History of receipt of the following:\n\n   * Investigational malaria vaccine in the last 2 years\n   * Immunoglobulins and/or blood products within 6 months of enrollment\n   * Investigational product within 3 months of enrollment\n   * Chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone ≥20 mg/day or equivalent) or immunosuppressive drugs within 30 days of enrollment\n   * Live vaccine within 30 days of enrollment\n   * Killed vaccine within 14 days of enrollment or planned receipt of a killed vaccine within 14 days of scheduled vaccination\n10. Known medical problems:\n\n    * Pre-existing autoimmune or antibody-mediated diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia)\n    * Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past two years, or that has required the use of oral or parenteral corticosteroids at any time during the past two years)\n    * Immunodeficiency disorder\n    * Asplenia or functional asplenia\n    * Diabetes\n    * Deep venous thrombosis or thromboembolic event\n    * Seizures (exception is simple febrile seizures during childhood)\n11. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Years","maximumAge":"10 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Patrick Duffy, MD","affiliation":"National Institute of Allergy and Infectious Diseases (NIAID)","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Issaka Sagara, MD MSPH PhD","affiliation":"Malaria Research and Training Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Malaria Research and Training Center","city":"Bamako","country":"Mali","geoPoint":{"lat":12.60915,"lon":-7.97522}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Arm 1 (PfSPZ Vaccine)","description":"Children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, and 29 days\n\nSanaria® PfSPZ Vaccine: non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf)."},{"id":"FG001","title":"Arm 2 (Normal Saline)","description":"Children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days\n\nNormal Saline: placebo control- saline"},{"id":"FG002","title":"Enrolled With no Arm Assignment","description":"Children ages 6 -10 were enrolled upon administration of AL treatment, but not assigned to a treatment arm (did not receive PfSPZ Vaccine nor Normal saline)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"139"},{"groupId":"FG001","numSubjects":"138"},{"groupId":"FG002","numSubjects":"13"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"138"},{"groupId":"FG001","numSubjects":"137"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"13"}]}],"dropWithdraws":[{"type":"Travel","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Parent/Guardian withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Disease progression/treatment failure","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Participant refusal","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm 1 (PfSPZ Vaccine)","description":"Children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, and 29 days\n\nSanaria® PfSPZ Vaccine: non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf)."},{"id":"BG001","title":"Arm 2 (Normal Saline)","description":"Children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days\n\nNormal Saline: placebo control- saline"},{"id":"BG002","title":"Enrolled With no Arm Assignment","description":"Children ages 6 -10 were enrolled upon administration of AL treatment, but not assigned to a treatment arm (did not receive PfSPZ Vaccine nor Normal saline)"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"290"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"290"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"116"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"174"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"290"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Mali","categories":[{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"290"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Possibly, Probably, or Definitely Related Serious Adverse Events (SAEs)","description":"Proportion of vaccinees compared to controls experiencing related SAEs from V1 to 26 weeks after V3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From day of first vaccination until 26 weeks after 3rd vaccination (study day 1 to day 211)","groups":[{"id":"OG000","title":"Arm 1 (PfSPZ Vaccine)","description":"Children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, and 29 days\n\nSanaria® PfSPZ Vaccine: non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf)."},{"id":"OG001","title":"Arm 2 (Normal Saline)","description":"Children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days\n\nNormal Saline: placebo control- saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Receipt of AL treatment to 26 weeks post 3rd vaccination (study day -17 to study day 211) = ~8 months","eventGroups":[{"id":"EG000","title":"Arm 1 (PfSPZ Vaccine)","description":"Children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, and 29 days\n\nSanaria® PfSPZ Vaccine: non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).","deathsNumAffected":0,"deathsNumAtRisk":139,"seriousNumAffected":0,"seriousNumAtRisk":139,"otherNumAffected":134,"otherNumAtRisk":139},{"id":"EG001","title":"Arm 2 (Normal Saline)","description":"Children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days\n\nNormal Saline: placebo control- saline","deathsNumAffected":0,"deathsNumAtRisk":138,"seriousNumAffected":0,"seriousNumAtRisk":138,"otherNumAffected":128,"otherNumAtRisk":138},{"id":"EG002","title":"Enrolled With no Arm Assignment","description":"Children ages 6 -10 were enrolled upon administration of AL treatment, but not assigned to a treatment arm (did not receive PfSPZ Vaccine nor Normal saline)","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":4,"otherNumAtRisk":13}],"otherEvents":[{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":139},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Blood creatinine increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Bronchitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":139},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":138},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":20,"numAtRisk":139},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Dermatosis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Ear infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":139},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Eye injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Face edema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":139},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Furuncle","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":139},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":138},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":139},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Genitourinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Gingivitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":19,"numAtRisk":139},{"groupId":"EG001","numEvents":23,"numAffected":22,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hemoglobin decrease","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hemoglobin increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hernia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hyperleukocytosis","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Influenza","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":139},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Malaria","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":141,"numAffected":86,"numAtRisk":139},{"groupId":"EG001","numEvents":146,"numAffected":90,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Mumps","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":138},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":139},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":139},{"groupId":"EG001","numEvents":26,"numAffected":22,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Otitis externa","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Paronychia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pruritus generalized","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pyoderma","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Rhinitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":96,"numAffected":62,"numAtRisk":139},{"groupId":"EG001","numEvents":83,"numAffected":57,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Sinobronchitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":22,"numAtRisk":139},{"groupId":"EG001","numEvents":26,"numAffected":23,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Tinea infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Torticollis","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Typhoid fever","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Varicella","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":139},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Wound infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":139},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":138},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Patrick Duffy","organization":"Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health","email":"patrick.duffy@nih.gov","phone":"301.761.5089"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-12-01","uploadDate":"2023-12-06T13:39","filename":"Prot_000.pdf","size":5471817},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-03-18","uploadDate":"2023-12-04T15:39","filename":"SAP_001.pdf","size":340334}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-12-26","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D008288","term":"Malaria"},{"id":"D016778","term":"Malaria, Falciparum"}],"ancestors":[{"id":"D011528","term":"Protozoan Infections"},{"id":"D010272","term":"Parasitic Diseases"},{"id":"D007239","term":"Infections"},{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077330","term":"Saline Solution"}],"ancestors":[{"id":"D000077324","term":"Crystalloid Solutions"},{"id":"D007552","term":"Isotonic Solutions"},{"id":"D012996","term":"Solutions"},{"id":"D004364","term":"Pharmaceutical Preparations"}]}},"hasResults":true}